Numerous studies have demonstrated that the interruption and restoration of the blood flow to the forebrain lead to the neuronal death in the CA1 region of the hippocampus, or transient ischemia [1, 2]. During ischemia, a series of events, such as the depletion of ATP, production of reactive oxygen species (ROS), an imbalance of intracellular calcium concentration, and changes in cellular pH, cause cellular damage, apoptosis and/or necrosis [3, 4]. Previous studies have suggested that anti-oxidant enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase can function as a defense mechanism against ROS-mediated cellular damage, thereby proposing that these anti-oxidant enzymes may be useful as a therapeutic agent against ROS-related diseases [5, 6].

Ribosomal proteins are essential components of ribosomes and highly conserved during evolution. Recently, it was reported that many ribosomal proteins could carry out extra-ribosomal functions in apoptosis, mRNA processing, DNA repair, and development.

Chlorogenic acid (CGA) possesses various biological activities such as anti-oxidant, anti-inflammatory, and anti-diabetic activities. In the present study, we examined the effect of CGA on the transduction efficiency of PEP-1-ribosomal protein S3 (PEP-1-rpS3) into cells and brain tissues, and its neuroprotective potential against ischemia/reperfusion. We found that, in the presence of CGA, the transduction efficiency of PEP-1-rpS3 into astrocytes and the CA1 region of the hippocampus was enhanced, compared to its transduction in the absence of CGA. Also, cell viability data demonstrated that the sample treated with CGA + PEP-1-rpS3 exhibited improved cell viability against hydrogen peroxide (H$_2$O$_2$)-induced toxicity more significantly than the sample treated with PEP-1-rpS3 alone. Also, in a gerbil ischemia model, data demonstrated that following the ischemic insult, the group treated with PEP-1-rpS3 + CGA showed markedly enhanced protection of neuron cells in CA1 region of hippocampus, compared to those treated with CGA or PEP-1-rpS3 alone. Taken together, these results suggest that CGA may improve the transduction efficiency of protein transduction domain (PTD) fusion proteins into target cells or tissues, thereby enhancing their therapeutic potential against various diseases.

Key words: chlorogenic acid, PEP-1-ribosomal protein S3, protein transduction, ischemic insult
Ribosomal protein S3 (rpS3) knockdown demonstrated that rpS3 is involved in nuclear factor-kappaB (NF-kB)-mediated gene regulations [9, 10]. Also, rpS3 has potential roles in processes such as DNA repair and apoptosis [11]. PEP-1-rpS3 was reported to protect the CA1 region of the hippocampus against cerebral ischemic damage [12].

Chlorogenic acid (CGA), a phenolic compound derived from herbs, is well-known for having various biological properties. For example, it was shown that CGA, as a natural anti-oxidant, effectively prevents iron-induced radical formation and exerts strong antimicrobial activity [13, 14]. Also, several studies revealed that CGA is an effective anti-inflammatory, analgesic and antipyretic agent in in vitro experiments and in vivo animal models [15-17]. Recently, numerous bio-molecules such as peptides and proteins, having therapeutic abilities, have been developed as new drug candidates. However, their large molecular sizes and poor hydrophilicities reduce and/or restrict their bioavailabilities or delivery to cells or tissues. Therefore, protein transduction domains (PTD), including trans-activator of transcription (Tat) (RKRRQRRKRR) from human immunodeficiency virus-1 and PEP-1 (KETWWET WTWESQP KKKRKV) derived from the nuclear localization sequence of simian virus 40, were developed to enhance the delivery of poor bioavailable drugs to cells or tissues [18-20]. In previous studies we reported that PTD fused proteins, such as PEP-1-rpS3, PEP-1-Frataxin and Tat-sensitive to apoptosis gene (Tat-SAG), can rapidly cross the blood-brain barrier (BBB) and provide neuronal protection against cerebral ischemic insults in ischemic animal models [21-23]. In addition, we demonstrated that several molecules, such as bog blueberry anthocyanins (BBA) and pergolide mesylate, have the potential to enhance the transduction efficiency of PTD-fused proteins into cells and animal tissues, thereby leading to improved therapeutic activity [24, 25]. Therefore, in this study, we examined whether CGA can enhance the transduction efficiency of PEP-1-rpS3 into astrocytes and brain tissues, and, consequently, can increase the potential of PEP-1-rpS3 to protect neuronal cells against ischemic insult.

MATERIALS AND METHODS

Materials and cell culture

CGA and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Primary antibodies against histidine and β-actin, and peroxidase conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other chemicals and reagents, unless otherwise stated, were obtained from Sigma-Aldrich (St. Louis, MO, USA). The astrocytes were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% heat-inactivated fetal bovine serum, 20 mM Hepes/NaOH (pH 7.4), 5 mM NaHCO3, and antibiotics (100 μg/ml streptomycin and 100 U/ml penicillin) and kept at 37°C under a humidified atmosphere of 95% air and 5% CO2.

Transductions of PEP-1 fusion proteins into astrocytes

PEP-1-rpS3 and PEP-1-green fluorescence protein (PEP-1-GFP) were purified as described previously [21]. To assess the concentration or time dependent transduction of PEP-1-rpS3 and PEP-1-GFP, cells were grown to confluence in wells of a 6-well plate, pretreated with or without CGA (100 ng/ml) for 1 h, and then exposed to various concentrations (0.5–2 μM) of each protein for an additional 1 h or exposed to each protein (2 μM) for various times (10–60 min). The cells were then harvested and cell extracts were prepared for Western blot analysis.

Western blot analysis

Equal quantities of β-actin normalized proteins from cell lysate were resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred to a nitrocellulose membrane, which was then blocked with 5% non-fat dry milk in PBS. To detect both PEP-1-rpS3 and PEP-1-GFP, which contain histidine sequence and PEP-1 domain, the membrane was probed with a rabbit anti-histidine polyclonal antibody (diluted at 1 : 10,000), followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (diluted at 1 : 10,000). The membrane was visualized by enhanced chemiluminescence according to the manufacturer’s instructions (Amer sham, Piscataway, NJ, USA).

Viability assay

An established assay based on MTT was used to assess cell viability [23]. Astrocytes were grown to 70% confluence in wells of a 96-well plate and pretreated with CGA (100 ng/ml) for 1 h. The cells were incubated with various concentrations of PEP-1-rpS3 (0.5–2 μM) for an additional 1 h and cell toxicity was induced by treatment with H2O2 (1 mM) for 4 h. Cellular viability was expressed as a percentage of a H2O2 untreated control.

Animals

Mongolian gerbils (Meriones unguiculatus) were purchased from the hallmark University Experimental Animal Center. They were permitted free access to food and water, ad libitum. All experimental procedures involving animals and their care conformed to the Guide for the Care and Use of Laboratory Animals of the National Veterinary Research & Quarantine Service of Korea and were...
approved by the Hallym Medical Center Institutional Animal Care and Use Committee.

**In vivo transduction of PEP-1-rpS3 into brain tissues**

To examine the effect of CGA on the transduction of PEP-1-rpS3 into brain tissues, CGA (100 μg/kg) was i.p. administered, followed by an i.p. injection of PEP-1-rpS3 (150 μg/kg) 1 h later. Brain biopsy samples were immunostained using a rabbit anti-histidine (1:400) and biotinylated goat anti-rabbit secondary antibodies (1:200). The sections were visualized with 3,3’-diaminobenzidine (DAB) in 0.1 M Tris buffer and observed under a microscope (Olympus DP72 digital camera, Tokyo, Japan).

**Induction of cerebral forebrain ischemia in experimental model**

To determine whether CGA affects the protective effect of PEP-1-rpS3 against ischemic damage, male Mongolian gerbils were randomly divided into 5 groups (n=7); sham-operated, vehicle treated, CGA-treated, PEP-1-rpS3-treated, and PEP-1-rpS3 + CGA treated groups. CGA dissolved in PBS was i.p. injected (100 μg/kg). Then, PEP-1-rpS3 (150 μg/kg) was administered i.p. 30 min prior to the occlusion of common carotid arteries. For the occlusion of common carotid arteries, gerbils were placed under general anesthesia with a mixture of 2.5% isoflurane (Abbott Laboratories, North Chicago, IL, USA) in 33% oxygen and 67% nitrous oxide. A midline ventral incision was made in the neck, and the common carotid arteries were isolated, freed of nerve fibers, and occluded with nontraumatic aneurysm clips. Complete interruption of blood flow was confirmed by observing the central artery in the eyeball using an ophthalmoscope. After 5 min occlusion, the aneurysm clips were removed. The restoration of blood flow (reperfusion) was observed directly under the ophthalmoscope. Sham-operated animals (n=7) were subjected to the same surgical procedures except that the common carotid arteries were not occluded. Rectal temperature was monitored and maintained at 37±0.5°C before, during, and after the surgery, until the animals had recovered fully from anesthesia. Immediately following ischemia-reperfusion, animals from each group were euthanized for cresyl violet staining.

**Tissue processing for histology**

All animals from each group were anesthetized with sodium pentobarbital and transcardially perfused with 4% paraformaldehyde in 0.1 M PBS (pH 7.4). Brain tissues were post-fixed in the same fixative for 4 h, followed by infiltration with 30% sucrose overnight. The tissues were then frozen and sectioned with a cryostat at 50 μm. Cresyl violet staining was performed as described previously [22,23].

**Statistical analysis**

Data are expressed as the means±SD. Comparison between groups was performed by Student’s t test. Values of p<0.01 and p<0.05 were considered to be statistically significant.

**RESULTS**

**CGA enhanced the transduction of PEP-1 fused proteins into astrocytes**

We previously reported that PEP-1-rpS3 can be effectively transduced into cells and animal tissues, thereby providing protection against UV damage or ischemic insult [12, 21]. To assess the effect of CGA on the transduction efficiency of PEP-1-fused proteins, we compared the extent of transduction of PEP-1-rpS3 and PEP-1-GFP into astrocytes in the presence or absence of CGA using Western blot analysis. The chemical structure of CGA and schematic sequences of PEP-1-rpS3 and PEP-1-GFP were shown in Fig. 1. As shown in Fig. 2, both PEP-1-rpS3 and PEP-1-GFP were delivered in a dose- and time-dependent manner to the cells without treatment of CGA. Particularly, when pretreated with CGA, a clear increase in the transduced amount of PEP-1-rpS3 and PEP-1-GFP was observed, compared to the samples without CGA pretreatment. These results demonstrated that CGA has the ability to improve the in vitro transduction of PEP-1 fused proteins.

**CGA produced no cellular toxicity**

We next examined whether the enhanced transduction of PEP-1-fusion proteins is ascribed to altered membrane permeability induced by CGA. As illustrated in Fig. 3, H₂O₂ (1 mM) produced apparent cell death to 44% of control cells. Although CGA is known to have anti-oxidant properties, CGA alone at the concentration (100 ng/ml) which was employed in our experiments failed to recover the cell viability against H₂O₂-induced oxidative stress. Cell viability did, however, increase with increasing concentrations of PEP-1-
rpS3 (0.5–2 μM). Moreover, co-treatment with PEP-1-rpS3 and CGA demonstrated further increases in cell viability, relative to the samples treated with PEP-1-rpS3 alone. At the maximal concentration of PEP-1-rpS3, CGA pretreatment enhanced cell viability, by approximately 11%. These data suggest that CGA can enhance the anti-oxidant activity of PEP-1-rpS3 without displaying any additional toxicity or anti-oxidative effects to astrocytes.

**In vivo transduction of PEP-1-rpS3 into the brain tissues was enhanced in the presence of CGA**

Next to verify whether CGA could increase the in vivo transduction of PEP-1-rpS3 as well, CGA was i.p. injected at a dose of 100 μg/kg 1 h prior to injection of PEP-1-rpS3 (150 μg/kg) and the distribution of PEP-1-rpS3 in the brain was identified by immunohistological staining. Fig. 4 shows results consistent with in vitro transduction of PEP-1-rpS3. RpS3 is not found in the brain tissues at all. The significant transduction of PEP-1-rpS3 was found in the CA1 regions of the hippocampus. In addition, much stronger signals in the same region were identified after combinational treatment with PEP-1-rpS3 + CGA than the sample treated with PEP-1-rpS3 alone, suggesting the effectiveness of CGA in the transduction of this fusion proteins.

**CGA apparently increased the neuroprotective effect of PEP-1-rpS3 against ischemic damage**

Transient ischemia induces the neuronal loss in the CA1 region of the hippocampus. We evaluated protection in each group against ischemia induction after the administration of CGA, PEP-1-rpS3, and CGA + PEP-1-rpS3 using cresyl violet staining and histological analysis. As shown in Fig. 5, most of cells in CA1 region in the vehicle-treated group were dead. Treatment with CGA
Effect of CGA on Protein Transduction

slightly increased the number of viable cells in the CA1 region and also treatment with PEP-1-rpS3 clearly exhibited enhanced protection against cell death in the CA1 region. Above all, the extent of neuronal protection in the sample treated with CGA + PEP-1-rpS3 was similar to that in the sham control, demonstrating that combinational treatment with CGA + PEP-1-rpS3 was much more protective against neuronal cell death induced by transient ischemia than that of CGA or PEP-1-rpS3 alone.

DISCUSSION

CGA is a polyphenol, which is abundantly found in coffee, fruits and vegetables. Several studies have provided evidence showing that CGA has various biological activities such as anti-oxidant, anti-inflammatory and analgesic. CGA has the ability to suppress 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced tumor promotion in a mouse model [26] and to induce p38 mitogen-activated protein kinase (MAPK)-dependent apoptosis in chronic myelogenous leukemic cells [27]. Also, the mechanism for anti-tumor activity of CGA suggests that, following treatment with UVB and TPA, CGA up-regulates cellular phase II anti-oxidant enzymes and suppresses activation of nuclear factor-kappa B (NF-κB), activator protein-1 (AP-1) and MAPK signaling pathways mediated by ROS [28]. CGA inhibits synthesis and release of inflammatory mediators, such as TNF-α and NO, and provides anti-inflammatory and analgesic activities in animal models of carrageenan-induced inflammation and formalin-induced pain [16]. Therefore, up-regulating levels of anti-oxidant enzymes in target cells or tissues can be proportional to the enhancement of therapeutic potentials of these enzymes. Increasing the intracellular levels of therapeutic proteins is also proposed as an effective therapy against several ROS-related diseases. Previously, we reported that, through fusion of rpS3 with PEP-1, one PTD, PEP-1-rpS3 can be effectively transduced into cells or brain tissues, suppress ROS generation and ischemic damage induced by oxidative stress, and functions as a neuroprotective agent [12]. In this study, we investigated a novel function of CGA to enhance the delivery of PEP-1 fusion proteins to cells and tissues, thereby increasing their cellular bioavailability and therapeutic potential. Our cell viability data demonstrated that, although CGA is well-known as an anti-oxidant molecule, CGA alone, at 100 ng/ml concentration, had no influence on H$_2$O$_2$-induced toxicity in

Fig. 5. CGA enhances the protective activity of PEP-1-rpS3 on hippocampus brain damage after ischemic insult. (A) CGA (100 μg/kg) was administered i.p. to gerbils and then PEP-1-rpS3 (150 μg/kg) was i.p. injected 30 min prior to ischemic damage. Hippocampi were removed after ischemia-reperfusion and stained with cresyl violet. The damaged area of brain tissue was CA1 of hippocampus. (B) Relative density of viable cells in CA1 region. Data were expressed as mean±S.D. (n=5/group). The asterisk indicates a statistically significant difference between vehicle-treated and other groups (*p<0.05, **p<0.01).
astrocytes (Fig. 3) and exhibited similar cell viability to the sample treated with H$_2$O$_2$. However, the existence of CGA improves the neuroprotective effect of PEP-1-rpS3 against H$_2$O$_2$, compared to the samples treated with PEP-1-rpS3 alone. Therefore, as we did not observe any clear neuroprotective effect of CGA alone, in this experiment we excluded the possibility that CGA provided any direct neuronal protection against H$_2$O$_2$ in the sample co-treated with CGA+PEP-1-rpS3. Next, to investigate the reason for the enhanced neuroprotective activity in the sample co-treated with CGA and PEP-1-rpS3, we examined whether treatment with CGA could affect transduction of PEP-1-rpS3 into astrocytes and subsequently enhance its neuroprotective effect against ischemic insult. As shown in Fig. 2, the transduction data show that treatment with CGA can considerably improve the transduction of PEP-1-rpS3 into astrocytes. Moreover, in vitro transduction data confirmed that PEP-1-rpS3, which has the ability to spontaneously cross the BBB, exhibited enhanced transduction into brain tissues in the presence of CGA (Fig. 4), as evidenced by in vitro transduction results. As a result of the enhanced transduction of PEP-1-rpS3 by CGA, an animal transient ischemia model provides the evidence that, even if CGA alone showed slight neuroprotection in the CA1 region of the hippocampus, CGA has the ability to definitely improve the transduction of PEP-1-rpS3 into brain tissues, resulting in improved neuroprotective effects of PEP-1-rpS3 against ischemic insult (Fig. 5).

Various biological activities of polyphenol such as CGA have been drawing much attention from many research groups. Because of the characteristic physicochemical properties of polyphenol, they chelate metals, scavenge ROS and exert a broad spectrum of biological activities [16,29]. On the other hand, our present study demonstrates that CGA also has the novel function of enhancing the transduction of PEP-1-fusion proteins beyond its already well-known anti-oxidant function. One reason for the different results may be that the function of CGA as an anti-oxidant in other literature was evaluated at the higher concentrations than that we used in this study. Moreover, others have suggested that there is a correlation between biological activity and the concentration of biomolecules. For instance, although (-)-epigallocatechin-3-gallate (EGCG), one of polyphenols, exhibited effective in vitro anti-cancer activity in the concentration of 10−100 μM, it is possible that its concentration in plasma or tissues was observed as very low by oral administration because of very poor bioavailability [29, 30]. Thus, it is considered that the concentration of CGA, cell lines, experimental conditions and assay methods may contribute to absolutely different results.

Many research groups have tried to explain how PTD could traverse the cellular membrane and the BBB. Although the mechanisms of PTD transduction are suggested such as a direct penetration via electrostatic interaction with negatively charged phospholipids, endocytosis-mediated pathways, and a formation of inverted micelles or pores structure, these mechanisms are still controversial [31-34]. Besides CGA, several molecules such as DMSO, BBA, and pergolide mesylate were reported to have the potential to enhance the transduction of PTD fusion proteins [24, 25, 30]. Even if, until now, it is still not clear which molecular events mediated by CGA or other molecules are responsible for enhancing the transduction of PTD fusion proteins, it is presumable that CGA might be related with one of the mechanism suggested above or increase permeability of the cellular membranes, subsequently facilitating transduction of PTD into cells and BBB. Therefore, additional studies are required to investigate molecules and pathways to take part in the process of transduction of PTD fusion proteins. Also, it is undoubtedly necessary to develop agents which could enhance transduction efficiency for therapeutic molecules having poor transduction efficiency.

Taken our results together, we demonstrate that CGA has the novel activity to significantly enhance transduction efficiency of PEP-1 fused therapeutic proteins into target cells or tissues, and, consequently, lead to improvement of their therapeutic potential.

**ACKNOWLEDGEMENTS**

This work was supported by the Mid-career Researcher Program grant (2009-0086319) and by the research grant from the Brain Research Center of the 21st Century Frontier Research Program (2010K0008080) and by the Priority Research Centers Program grant (2009-0093812) through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology.

**REFERENCES**

1. Kirino T (1982) Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 239:57-69
2. Petitot CK, Torres-Munoz J, Roberts B, Olarte JP, Nowak TS Jr, Pulsinelli WA (1997) DNA fragmentation follows delayed neuronal death in CA1 neurons exposed to transient global ischemia in the rat. J Cereb Blood Flow Metab 17:967-976
3. Floyd RA (1990) Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 4:2587-2597
4. Martone ME, Hu BR, Ellisman MH (2000) Alterations of hippocampal postsynaptic densities following transient ischemia. Hippocampus 10:610-616
5. Matés JM (2000) Effects of antioxidant enzymes in the molecular
control of reactive oxygen species toxicology. Toxicology 153: 83-104.
6. Muzykantov VR (2001) Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Release 71:1-21
7. Lindstrom MS (2009) Emerging functions of ribosomal proteins in gene-specific transcription and translation. Biochem Biophys Res Commun 379:167-170
8. Wool IG (1996) Extraribosomal functions of ribosomal proteins. Trends Biochem Sci 21:164-165
9. Wan F, Anderson DE, Barnitz RA, et al (2007) Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell 131:927-939
10. Wan F, Lenardo MJ (2010) The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res 20:24-33
11. Jang CY, Lee JY, Kim J (2004) RpS3, a DNA repair endonuclease and ribosomal protein, is involved in apoptosis. FEBS Lett 560: 81-85
12. Hwang IK, Yoo KY, Kim DW, et al (2008) Ischemia-induced ribosomal protein S3 expression changes and the neuroprotective effect against experimental cerebral ischemic damage. J Neurosci Res 86:1823-1835
13. Almeida AA, Farah A, Silva DA, Nunan EA, Glória MB (2006) Antibacterial activity of coffee extracts and selected coffee chemical compounds against enterobacteria. J Agric Food Chem 54:8738-8743
14. Kono Y, Kashine S, Yoneyama T, Sakamoto Y, Matsui Y, Shibata H (1998) Iron chelation by chlorogenic acid as a natural antioxidant. Biosci Biotechnol Biochem 62:22-27
15. Jin XH, Ohgami K, Shiratori K, et al (2006) Effects of blue honeysuckle (Lonicera caerulea L.) extract on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res 82:860-867
16. dos Santos MD, Almeida MC, Lopes NP, de Souza GE (2006) Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. Biol Pharm Bull 29:2236-2240
17. Sheu MJ, Chou PY, Cheng HC, et al (2009) Analgesic and anti-inflammatory activities of a water extract of Trachelospermum jasminoides (Apocynaceae). J Ethnopharmacol 126:332-338
18. Dietz GP (2010) Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research. Curr Pharm Biotechnol 11:167-174
19. Eggleton RD, Davis TP (1997) Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18:1431-1439
20. Wadia JS, Dowdy SF (2002) Protein transduction technology.

Curr Opin Biotechnol 13:52-56
21. Choi SH, Kim SY, An JJ, et al (2006) Human PEP-1-ribosomal protein S3 protects against UV-induced skin cell death. FEBS Lett 580:6755-6762
22. Kim DW, Lee SH, Jeong MS, et al (2010) Transduced Tat-SAG fusion protein protects against oxidative stress and brain ischemic insult. Free Radic Biol Med 48:969-977
23. Kim MJ, Kim DW, Yoo KY, et al (2010) Protective effects of transduced PEP-1-Frataxin protein on oxidative stress-induced neuronal cell death. J Neurosci 29:64-69
24. Lee SH, Jeong HJ, Kim DW, et al (2010) Enhancement of HIV-1 Tat fusion protein transduction efficiency by bog blueberry anthocyanins. BMB Rep 43:561-566
25. Sohn EJ, Kim DW, Kim YN, et al (2011) Effects of pergolide mesylate on transduction efficiency of PEP-1-ribosomal protein. Biochem Biophys Res Commun 406:336-340
26. Huang MT, Smart RC, Wong CQ, Conney AH (1988) Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48:5941-5946
27. Bandyopadhyay G, Biswas T, Roy KC, et al (2004) Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 104:2514-2522
28. Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M (2005) Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 280:27888-27895
29. Yang CS, Sang S, Lambert JD, Hou Z, Ju J, Lu G (2006) Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res 50:170-175
30. Wang H, Zhong CY, Wu JF, Huang YB, Liu CB (2010) Enhancement of TAT cell membrane penetration efficiency by dimesityl sulfoxide. J Control Release 143:64-70
31. Luo D, Saltzman WM (2000) Synthetic DNA delivery systems. Nat Biotechnol 18:33-37
32. Richard JP, Melikov K, Vives E, et al (2003) Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585-590
33. Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C, Heitz F (2004) Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 43:7698-7706
34. Deshayes S, Gerbal-Chaloin S, Morris MC, et al (2004) On the mechanism of non-endosomal peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 1667:141-147